Key result
Recent advances in identifying conserved cross-reactive antigenic sites and HRV reverse genetics suggest that developing a polyvalent or subunit human rhinovirus vaccine may be feasible despite the existence of over 150 distinct serotypes.
Developing an effective HRV vaccine remains challenging due to the vast antigenic diversity of the virus, despite early evidence that inactivated HRV can induce neutralizing antibodies.
Does not alter current respiratory infection prevention; leaves open polyvalent HRV vaccine feasibility pending trials.
Human rhinovirus (HRV) remains a leading cause of several human diseases including the common cold. Despite considerable research over the last 60 years, development of an effective vaccine to HRV has been viewed by many as unfeasible due, in part, to the antigenic diversity of circulating HRVs in nature. Over 150 antigenically distinct types of HRV are currently known which span three species: HRV A, HRV B, and HRV C. Early attempts to develop a rhinovirus vaccine have shown that inactivated HRV is capable of serving as a strong immunogen and inducing neutralizing antibodies. Yet, limitations to virus preparation and recovery, continued identification of antigenic variants of HRV, and logistical challenges pertaining to preparing a polyvalent preparation of the magnitude required for true efficacy against circulating rhinoviruses continue to prove a daunting challenge. In this review, we describe HRV biology, antigenic diversity, and past and present advances in HRV vaccine design.
No takes yet. Share an insight, caveat, or question.
Stobart et al. (2017) conducted a review in Human rhinovirus infection. Human Rhinovirus Vaccine was evaluated. Recent advances in identifying conserved cross-reactive antigenic sites and HRV reverse genetics suggest that developing a polyvalent or subunit human rhinovirus vaccine may be feasible despite the existence of over 150 distinct serotypes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: